2021 Managed Healthcare Executive® Pharmacy Survey: Drugs New to the Market Most Likely to Reduce Morbidity, Mortality
In this part five series, participants give their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.
In this portion of MHE's survey, respondents gave their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise.
Majority of respondents (26%) said Imcivree (setmelanotide), a drug for rare forms of obesity, would have the most promise to reduce morbidity and mortality when asked. Twenty-two percent of respondents said Oxlumo (lumasiran), a drug that treats primary hyperoxaluria type 1, shows more promise. Remaining respondents were for Zokinvy (lonafarnib) (22%), which is for rare conditions related to premature aging; 21% were for Orgovyx (relugolix), for prostate cancer; and 10% were for Evrysdi (risdiplam), a drug for spinal muscular atrophy.
When asked which drug in the pipeline shows more promise, participants responded with Farxiga (dapagliflozin), which treats chronic kidney disease in adults with or without type 2 diabetes, with a percentage at 35%. Roxadustat, a drug that treats anemia associated with chronic kidney disease, followed shortly behind at 31%. Participants (24%) also said Teplizumab, which is used for the prevention of type 1 diabetes, shows promise; while Valoctocogene roxaparvovec, a drug for severe hemophilia A, trailed behind at 24%.
Just over 225 people responded to our online survey between April 5 and May 10.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
